Alzamend Neuro, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 13, 2024, covers the results of the Adjourned Annual Meeting of Stockholders held on that date. The meeting was adjourned from April 30, 2024, to allow additional time for voting on Proposal 3, which was critical for the company to comply with Nasdaq Listing Rule 5635.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data disclosed relates to a specific capital transaction:
- Proposed Transaction Value: Up to $6,000,000.00.
- Instrument Details: Issuance of shares upon conversion of up to 6,000 shares of Series B Convertible Preferred Stock and exercise of warrants to purchase up to 6,000,000 shares of Common Stock.
- Counterparty: Ault Lending, LLC (under a Securities Purchase Agreement dated January 31, 2024).
Material Changes and Voting Results
The material change reported is the successful approval of Proposal 3, which had failed to pass at the initial Annual Meeting on April 30, 2024. At the Adjourned Meeting, stockholders approved the issuance of additional shares required for the Series B Transaction.
Voting Results for Proposal 3:
| Vote Category | Number of Votes |
|---|---|
| For | 2,787,961 |
| Against | 208,270 |
| Abstain | 49,368 |
| Broker Non-Votes | 1,679,673 |
Outstanding Voting Capital (as of March 14, 2024 Record Date):
- Common Stock: 6,849,407 shares
- Series B Preferred Stock: 1,220,000 shares
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the stockholder vote. The primary contingency addressed was the requirement to obtain stockholder approval to proceed with the Series B Transaction and maintain compliance with Nasdaq listing standards.
Key Facts for Investor Verification
- Verify the execution of the Securities Purchase Agreement with Ault Lending, LLC following the stockholder approval.
- Confirm the actual number of shares issued upon conversion of Series B Preferred Stock and exercise of warrants, as the filing only authorizes up to 6,000,000 shares.
- Review the definitive proxy statement on Schedule 14A (filed March 25, 2024) for detailed terms of the Series B Transaction.
- Monitor the company's cash position post-transaction, as the filing does not disclose current liquidity levels.